Please upgrade your browser.
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful...
TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and axitinib.
Wealth Transfer Planning Expert Ray Odom of the Northern Trust offers advice on how to avoid estate pitfalls that can lead to family friction – both before and after death.
With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies...
The research published indicated a relationship between height and an increased risk of cancer, a troublesome link, considering that the average height in the United States is 5′ 10″.
The rationale for a more aggressive approach
As the October 1st implementation approaches, public support for the Affordable Care Act has dropped below 40% in some surveys. Please take our poll, so that we know what families dealing with kidney cancer think about it.
Will the Affordable Care Act (aka “Obamacare”) implementation be successful? A doctor's opinion.
Sbangle is proud to announce its Orange Campaign for Kidney Cancer Association whereby 20% of all sales of Orange & Diamond Ribbon, Slim, and Napkin Rings will go to Kidney Cancer Association to help them continue to raise awareness of and funds for the prevention, early detection, and cure of kidney cancer.
Pazopanib demonstrated activity as a second-line treatment in patients with metastatic clear cell renal cell carcinoma who underwent first-line single-agent treatment with sunitinib or bevacizumab, according to results of a phase 2 trial.
|Powered by NeonCRM|